Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18822412 | 0.81 | DPP4 (0.39) | — | |
| SCHEMBL6143133 | 0.78 | TSHR (0.39) | LMNATSHRMAPTALOX15 | |
| SCHEMBL14615689 | 0.73 | LMNA (0.56) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28952330 | 0.73 | LMNA (0.56) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1982496 | 0.72 | SLC1A3 (0.34) | CHRM1CHRM3TSHRECE1 | |
| SCHEMBL3700073 | 0.71 | ALDH1A1 (0.42) | LMNATSHRALOX15 | |
| SCHEMBL5079956 | 0.71 | CA1 (0.42) | TSHR | |
| SCHEMBL638162 | 0.71 | ALDH1A1 (0.42) | LMNATSHRALOX15 | |
| SCHEMBL18359202 | 0.71 | CA1 (0.42) | TSHR | |
| SCHEMBL30561836 | 0.71 | CA1 (0.42) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071716-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |